CRISPR/Cas9 screens implicate RARA and SPNS1 in doxorubicin cardiotoxicity
W. Lv, Y. Shao, A. Hoshino…·C. McDermott-Roe
This study uses CRISPR/Cas9 screens to identify RARA and SPNS1 as genetic modifiers of doxorubicin cardiotoxicity, revealing their roles in cell death and drug accumulation.